GUANGZHOU, China, May 23, 2025 /PRNewswire/ -- As global demographics shift, the aging population becomes a defining force in product innovation. At the 137th China Import and Export Fair (Canton Fair), Chinese companies have been embracing this trend with technology-driven, senior-centric solutions designed to promote safety, independence, and dignity for older adults.
One standout exhibitor, Guangzhou SELAQUA Sanitary Ware Co., Ltd. (Aicube Care), drew attention with its modular bathroom systems tailored to senior users. Since entering the sector in 2010, the company has focused on high-end accessible designs, including a thermostatic shower panel with a built-in seat, an adjustable ceramic basin with a height-adaptable holder, U-shaped grab bars, and wall-mounted shower seats with supportive armrests and backrests. "As aging becomes a global issue, many buyers are realizing the growing demand in this sector," said Katie Peng, Sales Manager at Aicube Care. "Some who hadn't considered it before are now actively exploring opportunities after seeing our solutions."
Aging-focused innovation also featured prominently in the Canton Fair's first-ever Service Robots Zone. Zhejiang Fubao Intelligent Technology Co., Ltd. showcased an advanced companion robot built for elderly care. Equipped with AI-powered health monitoring, real-time physiological tracking, and telemedicine capabilities, the robot offers features such as blood oxygen detection, medication reminders, and emergency alert systems, all essential for seniors living independently.
Other senior-centric everyday solutions were exhibited during the 137th Canton Fair. Bio-based insoles with over 25% corn-derived PU provide superior cushioning and durability, offering seniors enhanced support for extended walking or standing. Meanwhile, height-adjustable, remote-controlled kitchens enable wheelchair users to effortlessly adjust cabinets and stoves to a comfortable working height.
On May 3rd, the Canton Fair hosted a themed event titled "Silver Economy: A New Paradigm for Aging-Friendly Products," further emphasizing its strong focus on this emerging trend.
From adaptive home fixtures to smart health monitoring systems, exhibitors at the 137th Canton Fair are redefining what it means to age with comfort and confidence. Their innovations show that designing for older adults is no longer a niche but a vital part of mainstream innovation. These companies are not just capitalizing on a significant growth opportunity. They are also advancing a broader social mission: making aging more inclusive, safe, and empowering. As these innovations reach global markets, the Fair continues to be a pivotal platform for shaping a future that embraces aging with compassion and foresight.
Photo - https://mma.prnasia.com/media2/2691605/image_969985_25478765.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Inclusive Design Gains Momentum as Canton Fair Spotlights Senior-Friendly Innovation
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
